Pål Møller

20.3k total citations · 1 hit paper
181 papers, 6.8k citations indexed

About

Pål Møller is a scholar working on Genetics, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Pål Møller has authored 181 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Genetics, 54 papers in Pathology and Forensic Medicine and 47 papers in Cancer Research. Recurrent topics in Pål Møller's work include BRCA gene mutations in cancer (99 papers), Genetic factors in colorectal cancer (53 papers) and Cancer Genomics and Diagnostics (46 papers). Pål Møller is often cited by papers focused on BRCA gene mutations in cancer (99 papers), Genetic factors in colorectal cancer (53 papers) and Cancer Genomics and Diagnostics (46 papers). Pål Møller collaborates with scholars based in Norway, United States and Canada. Pål Møller's co-authors include Ketil Heimdal, Ragnhild Husby, Steven A. Narod, Jan Lubiński, Lovise Mæhle, Henry T. Lynch, Hans F. A. Vasen, William D. Foulkes, Ping Sun and Charmaine Kim‐Sing and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Pål Møller

176 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history.

1993 673 citations Ketil Heimdal, Pål Møller et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pål Møller Norway	39	3.3k	2.6k	2.3k	1.9k	1.5k	181	6.8k
Lisa Cannon‐Albright United States	45	2.9k 0.9×	2.0k 0.8×	2.8k 1.2×	1.6k 0.8×	2.2k 1.5×	223	8.0k
Amanda B. Spurdle Australia	45	3.1k 1.0×	1.5k 0.6×	1.7k 0.8×	1.8k 0.9×	3.0k 2.0×	242	6.9k
Paul J. Goodfellow United States	51	2.2k 0.7×	2.7k 1.0×	2.8k 1.2×	3.0k 1.6×	5.1k 3.4×	222	11.1k
David E. Goldgar United States	45	3.1k 0.9×	1.3k 0.5×	1.7k 0.7×	1.3k 0.7×	2.3k 1.5×	128	6.7k
Hanne Meijers‐Heijboer Netherlands	40	2.5k 0.8×	917 0.3×	1.1k 0.5×	1.1k 0.5×	1.9k 1.3×	98	4.9k
Fiona Lalloo United Kingdom	39	2.4k 0.7×	1.6k 0.6×	1.7k 0.7×	1.5k 0.8×	1.1k 0.7×	119	5.0k
Tom Walsh United States	44	3.5k 1.1×	1.4k 0.5×	2.1k 0.9×	1.9k 1.0×	4.0k 2.7×	135	8.2k
Ingrid Winship Australia	36	1.4k 0.4×	1.4k 0.5×	1.3k 0.6×	829 0.4×	1.4k 0.9×	229	5.0k
Eric Legius Belgium	57	3.1k 1.0×	1.3k 0.5×	943 0.4×	750 0.4×	4.6k 3.1×	296	12.1k
Ketil Heimdal Norway	29	1.5k 0.5×	1.1k 0.4×	1.0k 0.5×	787 0.4×	1.2k 0.8×	103	3.6k

Countries citing papers authored by Pål Møller

Since Specialization

Citations

This map shows the geographic impact of Pål Møller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pål Møller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pål Møller more than expected).

Fields of papers citing papers by Pål Møller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pål Møller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pål Møller. The network helps show where Pål Møller may publish in the future.

Co-authorship network of co-authors of Pål Møller

This figure shows the co-authorship network connecting the top 25 collaborators of Pål Møller. A scholar is included among the top collaborators of Pål Møller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pål Møller. Pål Møller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morton, Katherine, Lesley Turner, Rebecca H. Foster, et al.. (2025). Optimizing risk‐reducing surgery and aspirin decision aids for Lynch syndrome carriers using the person‐based approach: A think‐aloud interview study. Journal of Genetic Counseling. 34(4). e70089–e70089.

Møller, Pål, Aysel Ahadova, Matthias Kloor, et al.. (2025). Colorectal carcinogenesis in the Lynch syndromes and familial adenomatous polyposis: trigger events and downstream consequences. Hereditary Cancer in Clinical Practice. 23(1). 3–3. 1 indexed citations

Bazo‐Alvarez, Juan Carlos, Patrik Wernhoff, Per Olaf Ekstrøm, et al.. (2022). Genetic Characterization in High-Risk Individuals from a Low-Resource City of Peru. Cancers. 14(22). 5603–5603. 1 indexed citations

Kim, Shana J., Jan Lubiński, Tomasz Huzarski, et al.. (2021). Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers & Prevention. 30(11). 2038–2043. 7 indexed citations

Seppälä, Toni T., Andrew Latchford, Ionuţ Negoi, et al.. (2020). European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. British journal of surgery. 108(5). 484–498. 145 indexed citations

Seppälä, Toni T., Mev Dominguez–Valentin, Julian R. Sampson, & Pål Møller. (2020). Prospective observational data informs understanding and future management of Lynch syndrome: insights from the Prospective Lynch Syndrome Database (PLSD). Familial Cancer. 20(1). 35–39. 14 indexed citations

Dominguez–Valentin, Mev, Sigve Nakken, Hélène Tubeuf, et al.. (2019). Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. Scientific Reports. 9(1). 18555–18555. 12 indexed citations

Dominguez–Valentin, Mev, Sigve Nakken, Hélène Tubeuf, et al.. (2018). Identification of genetic variants for clinical management of familial colorectal tumors. BMC Medical Genetics. 19(1). 26–26. 16 indexed citations

Møller, Pål, Neal Clark, & Lovise Mæhle. (2011). A simplified method for segregation analysis (SISA) to determine penetrance and expression of a genetic variant in a family. Human Mutation. 32(5). 568–571. 14 indexed citations

10.

Metcalfe, Kelly, Daphna Birenbaum‐Carmeli, Jan Lubiński, et al.. (2008). International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer. 122(9). 2017–2022. 261 indexed citations

11.

John, Esther M., Harvey A. Risch, Jan Lubiński, et al.. (2006). Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. The Lancet Oncology. 8(1). 26–34. 154 indexed citations

12.

Kotsopoulos, Joanne, Jan Lubiński, Susan L. Neuhausen, et al.. (2005). Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecologic Oncology. 100(1). 83–88. 32 indexed citations

13.

Geirdal, Amy Østertun, Jon Gerhard Reichelt, Alv A. Dahl, et al.. (2005). Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations. Familial Cancer. 4(2). 121–126. 35 indexed citations

14.

Møller, Pål. (2004). Costs and benefits of diagnosing familial breast cancer. Annals of Oncology. 15. i55–i59. 3 indexed citations

15.

Heimdal, Ketil, Lovise Mæhle, Jaran Apold, Jan Pedersen, & Pål Møller. (2003). The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. European Journal of Cancer. 39(15). 2205–2213. 33 indexed citations

16.

Møller, Pål, Åke Borg, Ketil Heimdal, et al.. (2001). The BRCA1 syndrome and other inherited breast or breast–ovarian cancers in a Norwegian prospective series. European Journal of Cancer. 37(8). 1027–1032. 24 indexed citations

17.

Møller, Pål, Jaran Apold, Lovise Mæhle, & Ketil Heimdal. (2000). [European guidelines for health care in hereditary breast cancer].. PubMed. 120(6). 726–7.

18.

Morrison, Patrick J., C. M. Steel, N. C. Nevin, et al.. (2000). Insurance considerations for individuals with a high risk of breast cancer in Europe:Some recommendations. Research Explorer (The University of Manchester). 3 indexed citations

19.

Dørum, Anne, Pål Møller, Erik-Jan Kamsteeg, et al.. (1997). A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. European Journal of Cancer. 33(14). 2390–2392. 21 indexed citations

20.

Vinje, Odd, Pål Møller, & O. J. Mellbye. (1980). Laboratory Findings in Patients with Psoriasis, with Special Reference to Immunological Parameters, Associations with Arthropathy and Sacro-Iliitis. Scandinavian Journal of Rheumatology. 9(2). 97–105. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact